Canadian dermatologists assess benefits of new treatments
A new biologic for psoriasis and a new tyrosine kinase-2 inhibitor for psoriasis, the long-term safety of
an IL-17 to treat pediatric patients with psoriasis, the availability of a new laser to treat acne, more options for atopic dermatitis (AD) patients, and expanding the use of deroofing in the management of
HS, are all advances that are highly encouraging to Canadian dermatologists.
Click here to read the full article.
